The results of the recently published Harmony-Outcomes study in The Lancet, led by Professor Stefano Del Prato, University of Pisa, Italy and Professor John McMurray, University of Glasgow, UK, have demonstrated that among patients with concomitant type 2 diabetes and cardiovascular disease, albiglutide, a glucagon-like peptide 1 receptor agonist is superior to placebo in the reduction of major adverse cardiovascular events. The study suggests that evidence-based glucagon-like peptide 1 receptor agonists should be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Continue reading
In an article published in the Journal of the American College of Cardiology, authored by Caroline Sindet-Pederson, MSc, and colleagues in the Department of Cardiology at Copenhagen University Hospital Herlev and Gentofte in Hellerup, Denmark, evaluating a real-world population of AF patients with MI and/or after PCI, the use of direct oral anticoagulants (DOAC) as compared to VKA reduced the risk of bleeding in patients also taking dual antiplatelet therapy (DAPT). Continue reading
In patients with acute myocardial infarction (MI) and a left ventricular ejection fraction (LVEF) equal or less than 35%, the use of wearable cardioverter defibrillator early after the MI did not lead to significant lowering of death from arrhythmia or from any cause, according to a new study published in the New England Journal of Medicine. Continue reading
The results of the Aspirin in Reducing Events in the Elderly (ASPREE) trial published in the New England Journal of Medicine showcase higher all-cause mortality among apparently healthy older adults receiving daily aspirin as compared to placebo, coupled with the shocking finding of mortality being attributed primarily to cancer, thereby painting a bleak picture of Aspirin (ASA) and heralding an end to its use in primary prevention. Continue reading
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study is a UK based trial that reports long-term beneficial effects of antihypertensives and statins in terms of mortality and cardiovascular outcomes after 16 years of follow-up in patients with hypertension. Continue reading
A randomized trial in patients with diabetes without evidence of cardiovascular disease has shown there to be no significant difference in the risk of serious cardiovascular events in those administered omega−3 fatty acids as compared to placebo. Continue reading
A recent study published in Circulation found that higher levels of low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDLC) increased the relative risk of long-term cardiovascular disease (CVD) mortality by 50% to 80%, in healthy participants that were considered to be at a low 10-year risk prior to the beginning of the study. Continue reading
A randomized controlled trial, originally published in 2013 which demonstrated a beneficial effect of Mediterranean diet on cardiovascular outcomes, was retracted because of randomization errors and republished in the June issue of NEJM 2018, with the correct data but the results were not changed substantially.
Dr. Sonia Anand Speaks at Brigham and Women’s Hospital
EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a randomized clinical trial, published in the Journal of the American Medical Association, provides evidence that smoking cessation medications do not increase the risk of serious cardiovascular events in the general population of smokers. Continue reading
Dr. John Eikelboom Speaks at Brigham and Women’s Hospital
In a recent study published in Circulation: Cardiovascular Interventions, Pracon et al. suggested that the incidence of device related thrombosis (DRT) among patients undergoing percutaneous left atrial appendage occlusion is related to patient (history of thromboembolic events and lower left ventricular ejection fraction) and procedural (deep implantation and larger occluder size) characteristics.
A recent study, published in the Journal of American College of Cardiology, concluded that there is a strong association of high sensitivity cardiac troponin (hs-cTn) with the risk of new-onset heart failure (HF), independent of population at risk, cardiovascular risk factors, and natriuretic peptide levels. Continue reading
A nationally representative, cross-sectional study published in Circulation highlighted the importance of cholesterol screening and statin prescription in patients with familial hypercholesterolemia (FH) and other forms of severe dyslipidemia. It was found that despite the high prevalence of cholesterol screening and awareness, only ≈50% of adults with FH are on statin therapy, with even fewer prescribed a high-intensity statin. Continue reading
In a recent article, published in The New England Journal of Medicine, the rates of major cardiovascular events with febuxosat were similar to allopurinol in patients with gout and concomitant cardiovascular disease. However, the mortality rates either due to cardiovascular deaths or any other cause were higher with febuxostat than allopurinol. Continue reading
The results of a cluster-randomized trial conducted in black barbershops have been published in the New England Journal of Medicine and were presented by Dr Ronald G. Victor from Los Angeles, California at the ACC 2018 Conference in Orlando. The study showed that health promotion by barbers along with medication management in barbershops by pharmacists, resulted in a larger blood pressure reduction in black male barbershop patrons with uncontrolled hypertension as compared to lifestyle modifications and doctor appointments.